Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Makes Financial Moves To Trim Cash Flow While Adding R&D

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical is suspending its three-year practice of buying back its own stock as it tightens its belt to increase research-and-development spending at the same time it continues to pay dividends. The 6 percent R&D budget increase is considered by Takeda as critical to plans to develop badly needed new drugs to replace expiring patents. Takeda has cut expenses elsewhere and plans not to increase its dividend to stockholders this fiscal year. The halt in stock buybacks also is intended to maintain its cash reserve. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts